CNR2 and melanoma: XTT assays demonstrated that ALDOC expression levels did not alter melanoma viability in either YDFR.CB3 or DP.CB2 ALDOC overexpressing cells (Fig. 2A) or in cells expressing downregulated ALDOC levels (data is not shown).